The latest domestic price of 2024 Rucapani/Rucapali

Rucaparib/Rucaparib belongs to a class of drugs called poly-ADP-ribose polymerase (PARP) inhibitors, which work by killing cancer cells. The original drug or generic drug of rucapanib has not yet been approved for marketing in China and may still be in the clinical research stage. Patients with domestic needs can only purchase this drug through relevant overseas channels, and the use of this drug must be under the guidance of a doctor.

Rucaparib is approved for use as a treatment to help maintain response to other treatments for certain types of ovarian cancer (cancer that begins in the female reproductive organ where eggs are formed), fallopian tube (the tubes that carry eggs released by the ovaries to the uterus), and primary peritoneal (the layer of tissue that surrounds the abdomen) cancer that has come back in adults who have had a complete or partial response to other chemotherapy treatments. It is also used to treat certain types of ovarian cancer, cancer of the fallopian tubes, and primary cancer in patients with a specific gene who have received at least two other types of chemotherapy. Rucaparib is also used to treat certain types of prostate cancer that have spread to other parts of the body in people with certain genes who have received other treatments.

Original drugs or generic drugs of rucapanib are already sold overseas. Common specifications are300mg*60 tablets and 200mg*60 tablets. The price of each box of the European original version may be more than 20,000 yuan (affected by exchange rates). (The price may fluctuate due to the impact of the price), the price is relatively expensive; the generic version of rucapani produced by India's BDR Pharmaceuticals may cost around 5-6 thousand yuan per box (the price may fluctuate due to the exchange rate), and the ingredients of the original drug remain basically the same.